Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0HQVXQ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Zarutatug vedotin
|
|||||
| Synonyms |
zarutatug vedotin; TORL-3-600
Click to Show/Hide
|
|||||
| Organization |
TORL Biotherapeutics (Originator)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Zarutatug
|
Antibody Info | ||||
| Antigen Name |
Cadherin-17 (CDH17)
|
Antigen Info | ||||
| Payload Name |
MMAE
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
vedotin
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Colorectal cancer |
1 Trials
|
||||||||
| Unspecific solid tumor |
1 Trials
|
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients must have advanced solid tumors with measurable disease (RECIST v1.1), ECOG 0-1, and adequate organ function. Exclusions include unresolved toxicities (>Grade 1, except alopecia), recent anticancer therapy (14-28 days prior), active brain metastases, uncontrolled comorbidities, cardiac disease, MDS/AML history, concurrent malignancies (except certain low-risk cases), and pregnancy/breastfeeding.
Click to Show/Hide
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05948826 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1, First in Human, Dose-Escalation Study of TORL-3-600 in Participants With Advanced Cancer | ||||
| Primary Endpoint |
The study will assess the incidence and severity of adverse events (AEs) and serious adverse events (SAEs) graded by NCI-CTCAE v5.0 over 2 years, while determining Maximum Tolerated Dose (MTD) based on dose-limiting toxicities (DLTs) in the first 6 evaluable participants within 28 days, and Recommended Phase 2 Dose (RP2D) using safety, tolerability, and pharmacokinetic data.
Click to Show/Hide
|
||||
| Other Endpoint |
Efficacy endpoints include Objective Response Rate (ORR), Duration of Response (DOR), Progression-Free Survival (PFS), Time to Response (TTR), 1-Year and 2-Year Overall Survival (1YOS, 2YOS), and immunogenicity via anti-drug antibody (ADA) assessment. Pharmacokinetic parameters [Cmax, Cmin, AUC, t1/2, CL, Vz, Rac, etc.] for TORL-3-600 will be evaluated over 21-63 days.
Click to Show/Hide
|
||||